Growth hormone (GH) is known as a hormone involved in regulation and influence of somatic growth but also of a long variety of metabolic pathways. GH exerts its effect in the body directly and indirectly, by stimulating insulin like growth factor-1 (IGF-1) production. Both GH and IGF-1 receptors are expressed in cardiac myocytes.
The aim of this study was to determine the effects of long-term GH treatment on heart anatomy and function among adult GH deficient patients.
Results from this study indicate that treatment duration of 8-10 years with GH replacement therapy in physiological doses in GH deficient patients appears not to be harmful, considering cardiac status. Verification of a positive effect of GH replacement on left ventricular mass index will, however, require a larger cohort of GHD patients.
Background and aim
Patients and methods
Results

Conclusions
All GH deficient patients followed at Rigshospitalet with available echocardiography data at treatment baseline, 3-5 years and 8-10 years follow up were included. 25 naïve GH deficient patients i.e. patients who had never received GH therapy before, and 16 semi-naive patients i.e.
patients previously on GH substitution therapy, but who had not received GH within 6 months before baseline evaluation.
Ultrasonic and biochemical data were collected retrospectively.
Echocardiographic assessments were performed in accordance with the recommendations of the American Society of Echocardiography with focus on left ventricular structure and function.  No significant difference was observed in cardiac structure, nor in cardiac systolic or diastolic function during long term GH therapy.
 When dividing the patient cohort into subgroups a decrease in diastolic function was observed among naïve and adulthood-onset patients.
 A non-significant positive correlation was observed between change in IGF-1 SDS versus change in LVMI, at 3-5 years and 8-10 years follow-up.
